FDA Accepts BrainStorm's NurOwn® IND Application for Progressive Multiple Sclerosis; U.S. Phase 2 Study to Begin in First Quarter of 2019    

Press/Media

Period17 Dec 2018

Media coverage

1

Media coverage

  • TitleFDA Accepts BrainStorm's NurOwn® IND Application for Progressive Multiple Sclerosis; U.S. Phase 2 Study to Begin in First Quarter of 2019    
    Media name/outletPrimeNewswire (Top News)
    Country/TerritoryUnited States
    Date17/12/18
    PersonsFred Lublin